A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
Status:
Completed
Trial end date:
2019-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of
JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset
and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant)
upon multiple (14 days) dose administration in participants with insomnia disorder.